Clinical Trial

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Study acronym: REFRACT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of the REFRACT clinical trial is to find new therapies with improved outcomes compared to the current standard treatment available, in patients with relapsed or refractory follicular lymphoma. This will be done by comparing patients who have received a new treatment against patients who receive standard treatment based on their response to the treatment received.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-04-28; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2023-07-18
Trial Details
NCT Number NCT05848765
Lead Sponsor University of Birmingham
Collaborators: Cancer Research UK, Genmab
Conditions Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
Enrollment 284 participants
Start Date 2023-09-04
Primary Completion 2029-05-31 (estimated)
Study Completion 2031-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-05